CYNAF risk analysis
|
Use CYNAF risk analysis together with your otc stock portfolios to protect against small markets fluctuations and to determine OTC Stock optimization strategy that fits your criteria. Suggest Portfolio
Projected Return Density against MarketAssuming 30 trading days horizon, CYNAF has beta of -4.28 . This suggests as returns on its benchmark rise, returns on holding CYNAF are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, CYNAF is expected to outperform its benchmark. Additionally, CYNAF has negative alpha implying that risk taken by holding this securing is not justified. The company is significantly underperforming S&P 500
Actual Return VolatilityCYNAF accepts 5.84% volatility on return distribution over the 30 days horizon. S&P 500 shows 0.55% volatility of returns over 30 trading days. |
Follow CYNAF Volatility with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker CYNAF has a volatility of 5.84 and is 10.62 times more volatile than S&P 500. 77% of all equities and portfolios are less risky than CYNAF. Compared with the overall equity markets, volatility of historical daily returns of CYNAF is higher than 77 (%) of all global equities and portfolios over the last 30 days. Use CYNAF to protect against small markets fluctuations. The otc stock experiences no pattern. Wait for more market signals and watch out for any hype. As returns on market increase, returns on owning CYNAF are expected to decrease by larger amounts. On the other hand, during market turmoil, CYNAF is expected to significantly outperform it. CYNAF correlation with marketVery good diversificationOverlapping area represents amount of risk that can be diversified away by holding PSUS THERAPEUTIC and equity matching GSPC index in the same portfolio CYNAF Current Risk Indicators
Suggested Divercification Pairs |